国金证券股份有限公司 关于浙江联盛化学股份有限公司 2024 年度 募集资金存放与使用情况的核查意见 国金证券股份有限公司（以下简称"保荐机构"或"国金证券"）作为浙江联盛 化学股份有限公司（以下简称"联盛化学"或"公司"）首次公开发行股票并在创业 板上市及持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》《上市 公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》等有关法律法规及规范性文件的规定，对公司 2024 年度募集资金存放与使用情况进行了核查，具体情况如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证监会以"证监许可〔2022〕413 号"文批复同意，公司向社会公众 公开发行人民币普通股（A 股）股票 2,700 万股，每股发行价为 29.67 元，共募 集资金 80,109.00 万元。在扣除发行费用 7,405.93 万元后，募集资金净额为 72,703.07 万元。前述募集资金到位情况业经天健会计师事务所(特殊普通合伙)验 证，并由其出具了 ...

国金证券股份有限公司 关于浙江联盛化学股份有限公司 使用部分暂时闲置募集资金进行现金管理及自有资金 进行委托理财的核查意见 国金证券股份有限公司（以下简称"国金证券"或"保荐机构"）作为浙江联盛 化学股份有限公司（以下简称"联盛化学"或"公司"）首次公开发行股票并在创业 板上市及持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》《上市 公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》等有关法律法规的规定，对公司使用部分暂时闲置 募集资金进行现金管理及自有资金进行委托理财事项进行了核查，具体核查情况 如下： 一、募集资金基本情况 经中国证券监督管理委员会于 2022 年 2 月 28 日发布的"证监许可〔2022〕 413 号"《关于同意浙江联盛化学股份有限公司首次公开发行股票注册的批复》， 同意公司首次公开发行人民币普通股(A 股)股票 2,700 万股，每股面值 1 元，发 行价格为每股人民币 29.67 元，募集资金总额为人民币 80,109.00 万元，扣除发 行费用 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥176,688,793.53, representing a 31.32% increase compared to ¥134,549,472.48 in the same period last year[4] - Net profit attributable to shareholders was ¥11,175,282.28, up 39.66% from ¥8,001,565.58 year-on-year[4] - The net profit excluding non-recurring gains and losses increased by 60.10% to ¥10,117,891.83 from ¥6,319,799.07 in the previous year[4] - Basic and diluted earnings per share rose to ¥0.10, a 42.86% increase from ¥0.07 in the same period last year[4] - Total operating revenue for the current period reached ¥176,688,793.53, an increase of 31.3% compared to ¥134,549,472.48 in the previous period[20] - Net profit for the current period was ¥11,641,356.18, representing a 32.3% increase from ¥8,767,971.22 in the previous period[22] - Earnings per share (EPS) for the current period was ¥0.10, compared to ¥0.07 in the previous period[22] Assets and Liabilities - The total assets at the end of Q1 2025 were ¥1,713,352,169.16, reflecting a 1.52% increase from ¥1,687,737,410.13 at the end of the previous year[4] - Total current assets decreased slightly to ¥721,990,703.10 from ¥731,163,266.12[17] - Total liabilities increased to ¥305,455,562.26 from ¥291,947,347.90, indicating a rise in short-term borrowings[17] - The company's total assets stand at ¥1,713,352,169.16, up from ¥1,687,737,410.13[17] - Total liabilities amounted to ¥330,096,959.00, compared to ¥316,977,020.15 in the previous period[18] - Total equity attributable to shareholders of the parent company was ¥1,351,900,960.08, an increase from ¥1,339,872,213.80 in the previous period[18] Cash Flow - Cash flow from operating activities decreased by 27.95% to ¥10,091,294.39 from ¥14,005,060.14 year-on-year[4] - Cash inflow from operating activities totaled ¥147,784,344.63, an increase from ¥134,564,635.99 in the previous period[24] - The net cash flow from operating activities was CNY 10,091,294.39, a decrease of 28.5% compared to CNY 14,005,060.14 in the previous period[25] - Cash inflow from investment activities totaled CNY 49,883,135.95, down 65.0% from CNY 142,806,265.19 in the prior period[25] - The net cash flow from investment activities was CNY 3,310,538.94, a significant decrease of 95.8% compared to CNY 78,848,297.85 in the previous period[25] - Cash inflow from financing activities was CNY 1,086,260.45, a decrease of 46.9% from CNY 2,041,576.33 in the prior period[25] - The total cash and cash equivalents at the end of the period amounted to CNY 74,226,747.09, down 71.5% from CNY 260,333,086.05 at the end of the previous period[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 8,483[13] - The largest shareholder, Liansheng Chemical Group, holds 52.78% of shares, totaling 57,000,000 shares[13] Operational Metrics - The company reported a significant increase in prepayments, which rose by 135.21% to ¥16,653,221.75 due to higher advance payments for raw materials[10] - Investment income surged by 226.57% to ¥198,656.81, attributed to the redemption of financial products exceeding the previous year's amount[11] - The company experienced a 95.80% decline in net cash flow from investing activities, dropping to ¥3,310,538.94 from ¥78,848,297.85 year-on-year[11] - The accounts receivable increased to ¥107,004,672.66 from ¥103,647,203.66, reflecting a growth in sales[16] - Inventory decreased to ¥87,486,312.81 from ¥95,111,078.72, suggesting improved inventory management[16] - The company has a significant investment in construction projects, with ongoing projects valued at ¥584,937,869.19[17] - The company reported a decrease in employee compensation liabilities to ¥5,167,418.00 from ¥13,837,761.71, indicating potential cost-cutting measures[17] - Research and development expenses increased to ¥4,219,150.75, up from ¥3,672,063.05 in the previous period[21] Tax Liabilities - Deferred income tax liabilities rose to ¥103,546.11 from ¥53,450.48 in the previous period[18]

Financial Performance - The company's operating revenue for 2024 was ¥632,455,319.20, a decrease of 4.47% compared to ¥662,015,730.44 in 2023[18]. - Net profit attributable to shareholders for 2024 was ¥17,258,892.78, down 75.73% from ¥71,112,773.72 in 2023[18]. - The net profit excluding non-recurring gains and losses for 2024 was ¥14,848,697.94, a decline of 77.84% from ¥67,011,804.83 in 2023[18]. - The basic earnings per share for 2024 was ¥0.16, a drop of 75.76% compared to ¥0.66 in 2023[18]. - The total assets at the end of 2024 were ¥1,687,737,410.13, reflecting a slight increase of 0.25% from ¥1,683,513,672.39 at the end of 2023[18]. - The company reported a negative cash flow from operating activities of ¥134,558,922.12 in 2024, compared to a positive cash flow of ¥193,755,940.16 in 2023, marking a 169.45% decline[18]. - The company achieved a gross margin of 10.19% in 2024, down from the previous year, with a cost of sales amounting to ¥568,003,827.72[76]. - The company reported a significant asset impairment of -2,624,168.87, accounting for -14.89% of total profit, mainly due to inventory write-downs[93]. - The company’s total revenue for 2024 was ¥632,455,319.20, representing a decrease of 4.47% compared to ¥662,015,730.44 in 2023[74]. Dividend Distribution - The company plans to distribute a cash dividend of 1.20 RMB per 10 shares (before tax) to all shareholders, based on a total of 108,000,000 shares[5]. - The total cash dividend represents 100% of the total distributable profit of 353,097,267.93 CNY[195]. - The company has not issued any bonus shares or capital reserve transfers during this profit distribution[196]. - The cash dividend distribution is in line with the company's articles of association and dividend management measures[194]. - The company plans to distribute a cash dividend of 1.20 CNY per 10 shares, totaling 12,960,000 CNY for the current fiscal year[196]. Market and Industry Trends - The chemical industry showed a 4.2% year-on-year increase in operating revenue for the manufacturing of chemical raw materials and products in 2024[28]. - The global pharmaceutical market is projected to grow from $1,324.5 billion in 2019 to $1,472.3 billion in 2023, with a compound annual growth rate (CAGR) of 2.7%[36]. - China's pharmaceutical market reached $231.5 billion in 2023, second only to the United States, and is expected to grow to $373.2 billion by 2030[36]. - The demand for wet electronic chemicals in China reached 2.633 million tons in 2022, representing a year-on-year growth of 21.83%[41]. - The global market for wet electronic chemicals is estimated to be approximately ¥68.4 billion in 2023, projected to reach ¥82.8 billion by 2025[42]. - The fine chemical industry is experiencing a shift towards high value-added products, driven by increasing demand for high-performance and high-purity chemicals[122][123]. Product and Innovation Strategy - The company is focusing on product innovation and technological upgrades to enhance core competitiveness and achieve differentiated competition[4]. - The company aims to enhance its competitive edge through continuous technological innovation and process optimization[43]. - The company is focusing on three main business segments: fine chemicals, electronic chemicals, and biodegradable new materials, emphasizing green and low-carbon development[43]. - The company has established multiple joint laboratories with renowned universities to enhance its R&D capabilities and foster innovation[32]. - The company is committed to developing high-end chemical new materials and fine chemicals, capitalizing on significant market opportunities[44]. Operational Efficiency and Cost Management - The company is implementing lean production practices and energy-saving automation modifications to improve production efficiency and reduce costs[4]. - The company has implemented digital and intelligent production management across its entire production process using DCS system control[43]. - The company has implemented cost-reduction measures, optimizing procurement and production processes, which contributed to improved operational efficiency[71]. - The company aims to enhance trade digitalization development levels as a pilot unit in Taizhou, improving service efficiency for downstream customers[62]. - The company has a complete procurement, production, and sales system, allowing for independent operations based on market changes[47]. Risk Management - The company acknowledges various risks, including macroeconomic fluctuations, raw material price volatility, and environmental compliance risks, which may impact future operations[5]. - The company faces challenges due to insufficient effective demand and severe homogenization competition within the chemical industry[28]. - The company is aware of macroeconomic risks affecting its operations and plans to enhance its core competitiveness through increased R&D efforts and timely market responses[133]. - The company faces risks from fluctuations in raw material prices, which could increase procurement and production costs, potentially impacting profitability[134]. - The company is monitoring exchange rate fluctuations closely, as a significant portion of its sales is denominated in USD, which could impact financial performance[139]. Governance and Management - The company has established an independent and complete operational system, ensuring independence from its controlling shareholders in assets, personnel, finance, and business operations[156]. - The company maintains a fully independent financial department, capable of making autonomous financial decisions and managing its own bank accounts[160]. - The company has a clear governance structure, with independent directors and a mix of internal and external appointments[167]. - The company is focused on maintaining continuity in its management team while also refreshing its board with new talent[166]. - The company has actively organized compliance training for management to enhance governance and risk management awareness[198]. Employee and Talent Management - The company has established a competitive salary system to attract and retain talent, with differentiated salary structures based on position and performance[189]. - The company has a comprehensive training system, offering various training programs to enhance employee skills and align personal development with corporate growth[191]. - The company has a total of 411 employees, with 278 in production, 11 in sales, 50 in technology, 10 in finance, and 62 in administration[188]. - The company has implemented a stable profit distribution policy, ensuring clear standards and procedures for dividend distribution to shareholders[192]. Research and Development - The company aims to enhance product competitiveness and market resilience through ongoing R&D projects in pharmaceutical intermediates and fine chemicals[86]. - The company will enhance R&D innovation, particularly in high value-added products such as electronic chemicals and pharmaceutical intermediates, to maintain a technological edge[126]. - R&D investment amount in 2024 was ¥20,391,764.66, down 20.25% from ¥25,566,012.19 in 2023, with R&D expenditure accounting for 3.22% of operating revenue[87].

浙江联盛化学股份有限公司 2024 年度独立董事述职报告 （阮涛涛先生） 作为浙江联盛化学股份有限公司（以下简称"公司"）的独立董事，在 2024 年度履职期间，本人严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》《上市公司独立董事管理办法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》以及《浙江联盛化学股份有限公司章程》（以下简称"《公 司章程》"）、《浙江联盛化学股份有限公司独立董事工作制度》等有关规定和 要求，诚信、勤勉、独立地履行职责，有效发挥独立董事的作用，较好地维护了 公司及全体股东的合法权益。现将 2024 年度的履职情况汇报如下： 一、独立董事基本情况 （一）独立董事工作履历、专业背景以及兼职情况 阮涛涛，1985 年出生，中国国籍，无境外永久居留权，本科学历，律师。 2009 年至今，历任浙江利群律师事务所实习律师、律师、合伙人；2020 年至今， 担任公司独立董事。 （二）独立性情况自查说明 本人作为公司独立董事，未在公司兼任除董事会专门委员会主任委员或委员 外的其他任何职务；本人及直 ...

浙江联盛化学股份有限公司 2024 年度独立董事述职报告 （葛昌华先生） 作为浙江联盛化学股份有限公司（以下简称"公司"）的独立董事，2024 年，我严格按照《中华人民共和国公司法》《中华人民共和国证券法》《深圳证 券交易所创业板股票上市规则》以及《浙江联盛化学股份有限公司章程》（以下 简称《公司章程》）、《浙江联盛化学股份有限公司独立董事工作制度》等相关 规定，忠实履行独立董事职责，积极出席公司相关会议，对公司的生产经营和业 务发展提出合理的建议，充分发挥独立董事的作用，维护公司股东尤其是中小股 东的合法权益。现将 2024 年度的履职情况报告如下： 一、独立董事的基本情况 葛昌华，1964 年出生，中国国籍，无境外永久居留权，本科学历，副教授。 1986 年至 1994 年，任临海化肥厂技术科科长；1994 年至 2001 年，任台州师范 专科学校教师；2001 年至 2024 年，任台州学院教师；2019 年至今，担任公司独 立董事。 我除了担任公司独立董事及董事会各专门委员会相关主任委员或委员外，未 在公司担任其他任何职务；未持有公司股份；与持有公司 5%以上股份的股东、 实际控制人、公司其他董事、监 ...

本人金礼才，1982 年出生，中国国籍，无境外永久居留权，本科学历，高 级会计师、注册会计师、税务师。2016 年 1 月至 2018 年 12 月，任浙江中永中 天会计师事务所有限公司部门经理；2019 年 1 月至 2021 年 12 月，任浙江中永 中天会计师事务所有限公司总经理助理；2022 年 1 月至今，任浙江中永中天会 计师事务所有限公司董事、副总经理；2014 年 8 月至今，任台州知联中天税务 师事务所有限公司路桥分公司负责人；2016 年 1 月至 2024 年 11 月，任台州知 联中天税务师事务所有限公司董事；2023 年 11 月至今，任浙江联盛化学股份有 限公司独立董事；2024 年 1 月至今，任浙江百达精工股份有限公司独立董事。 （二）是否存在影响独立性的情况说明 浙江联盛化学股份有限公司 2024 年度独立董事述职报告 （金礼才先生） 作为浙江联盛化学股份有限公司（以下简称"公司"）的独立董事，根据《中 华人民共和国公司法》《中华人民共和国证券法》《上市公司独立董事管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公 ...

浙江联盛化学股份有限公司 舆情管理制度 浙江联盛化学股份有限公司 舆情管理制度 第一章 总 则 第一条 为了提高浙江联盛化学股份有限公司 以下简称"公司"）应对各类舆 情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公司股价 及其衍生品、公司商业信誉及正常生产经营活动造成的影响，切实保护投资者和 公司的合法权益，根据 中华人民共和国公司法》 中华人民共和国证券法》 深 圳证券交易所股票上市规则》 深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》等相关法律法规、规范性文件及 浙江联盛化学股 份有限公司章程》 以下简称" 公司章程》"），结合公司实际情况，特制订本 制度。 第二条 本制度所称舆情包括： (一) 报刊、电视、网络等媒体及自媒体 以下合称 媒体"）对公司进行的 负面报道、不实报道； (三) 可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信 息； (四) 其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较 大影响的事件信息。 第三条 舆情信息的分类： (一) 重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活动， 使公司已经或可能遭受 ...

非经营性资金占用及其他关联资金 往来情况专项说明 浙江联盛化学股份有限公司 容诚专字[2025]100Z1000 号 容诚会计师事务所(特殊普通合伙) 中国·北京 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 关于浙江联盛化学股份有限公司 非经营性资金占用及其他关联资金往来情况专项说明 容诚专字[2025]100Z1000 号 浙江联盛化学股份有限公司全体股东： 我们接受委托，依据中国注册会计师审计准则审计了浙江联盛化学股份有限 公司（以下简称联盛化学公司）2024 年 12 月 31 日的合并及母公司资产负债表， 2024 年度的合并及母公司利润表、合并及母公司现金流量表和合并及母公司所有 者权益变动表以及财务报表附注，并于 2025 年 4 月 23 日出具了容诚审字 [2025]100Z1927 号的无保留意见审计报告。 根 ...

浙江联盛化学股份有限公司 2024 年财务决算报告 一、2024 年度公司整体经营情况 2024 年度，浙江联盛化学股份有限公司（以下简称或"公司"）全年实现营 业总收入为 632,455,319.20 元，同比下降 4.47%；归属于上市公司股东的净利 润为 17,258,892.78 元，同比下降 75.73%。 二、2024 年度公司财务报告审计情况 公司 2024 年度财务报表已经容诚会计师事务所（特殊普通合伙）审计，并 出具了容诚审字〔2025〕100Z1927 号标准无保留意见的审计报告。 三、2024 年度主要财务数据和指标 单位：元 | 项目 | 2024 年 | 2023 年 | 本年比上年增减 | | --- | --- | --- | --- | | 营业收入 | 632,455,319.20 | 662,015,730.44 | -4.47% | | 归属于上市公司股东的净 | 17,258,892.78 | 71,112,773.72 | -75.73% | | 利润 | | | | | 归属于上市公司股东的扣 | 14,848,697.94 | 67,011,804.83 | -7 ...